AAPL328.22+3.26 (+1.00%) ▲|ABBV260.89-0.83 (-0.32%) ▼|ABT108.63-1.85 (-1.67%) ▼|ACN194.49+6.81 (+3.63%) ▲|ADBE284.31+4.52 (+1.61%) ▲|AMAT435.58-2.88 (-0.66%) ▼|AMD457.58+0.52 (+0.11%) ▲|AMGN444.03+1.19 (+0.27%) ▲|AMT177.67+4.75 (+2.75%) ▲|AMZN258.45+3.47 (+1.36%) ▲|AVGO354.44-12.80 (-3.49%) ▼|AXP330.27+0.29 (+0.09%) ▲|BA208.90+0.03 (+0.01%) ▲|BAC63.04+0.44 (+0.69%) ▲|BKNG196.53-3.07 (-1.54%) ▼|BLK1,115.05+7.97 (+0.72%) ▲|BMY67.86+0.20 (+0.29%) ▲|BNY163.70+1.66 (+1.02%) ▲|BRK-B507.73+2.49 (+0.49%) ▲|C137.87+3.53 (+2.62%) ▲|CAT796.71+4.43 (+0.56%) ▲|CL90.29+0.19 (+0.21%) ▲|CMCSA26.62-0.19 (-0.70%) ▼|COF219.85+3.25 (+1.50%) ▲|COP136.18-1.02 (-0.74%) ▼|COST928.93+0.45 (+0.05%) ▲|CRM264.64+7.71 (+3.00%) ▲|CSCO109.03-0.43 (-0.39%) ▼|CVS97.77+0.54 (+0.56%) ▲|CVX212.65+0.87 (+0.41%) ▲|DE693.95-4.42 (-0.63%) ▼|DHR208.54-1.37 (-0.65%) ▼|DIS107.62-0.36 (-0.33%) ▼|DUK121.66+1.10 (+0.91%) ▲|EMR149.81+0.83 (+0.55%) ▲|FDX320.65+4.11 (+1.30%) ▲|GD364.06-0.01 (0.00%) ▼|GE332.16+2.66 (+0.81%) ▲|GEV942.92+20.98 (+2.28%) ▲|GILD149.98+0.37 (+0.25%) ▲|GM86.82+1.95 (+2.30%) ▲|GOOG338.90+5.12 (+1.53%) ▲|GOOGL342.31+5.19 (+1.54%) ▲|GS1,034.79+30.37 (+3.02%) ▲|HD318.96+2.78 (+0.88%) ▲|HON207.92+1.85 (+0.90%) ▲|IBM233.68+1.98 (+0.85%) ▲|INTC91.24+1.19 (+1.32%) ▲|INTU347.75+4.81 (+1.40%) ▲|ISRG370.25-1.64 (-0.44%) ▼|JNJ278.23+3.02 (+1.10%) ▲|JPM361.28+5.06 (+1.42%) ▲|KO88.96+0.72 (+0.82%) ▲|LIN483.22-2.63 (-0.54%) ▼|LLY1,159.84-0.25 (-0.02%) ▼|LMT531.82+0.27 (+0.05%) ▲|LOW202.50+2.66 (+1.33%) ▲|LRCX287.79-0.53 (-0.18%) ▼|MA584.13-4.01 (-0.68%) ▼|MCD259.17-1.78 (-0.68%) ▼|MDLZ61.29-1.16 (-1.86%) ▼|MDT92.77+0.59 (+0.63%) ▲|META612.97+20.12 (+3.39%) ▲|MMM167.92-0.83 (-0.49%) ▼|MO69.87+0.31 (+0.44%) ▲|MRK151.70+0.06 (+0.04%) ▲|MS216.37+4.55 (+2.15%) ▲|MSFT510.21+13.39 (+2.70%) ▲|MU940.98-15.11 (-1.58%) ▼|NEE83.99+0.89 (+1.07%) ▲|NFLX82.32-0.41 (-0.50%) ▼|NKE38.58+0.34 (+0.88%) ▲|NOW143.96+7.24 (+5.30%) ▲|NVDA227.10+2.69 (+1.20%) ▲|ORCL154.63+8.88 (+6.09%) ▲|PEP139.76-0.77 (-0.54%) ▼|PFE28.81-0.21 (-0.72%) ▼|PG147.69+0.05 (+0.03%) ▲|PLTR182.95+13.49 (+7.96%) ▲|PM187.63-0.32 (-0.17%) ▼|QCOM169.26+0.22 (+0.13%) ▲|RTX201.61+0.83 (+0.41%) ▲|SBUX106.14-0.58 (-0.54%) ▼|SCHW110.13+1.89 (+1.75%) ▲|SO89.14+0.83 (+0.94%) ▲|SPG211.31+1.11 (+0.53%) ▲|T26.18+0.23 (+0.87%) ▲|TMO609.78+1.24 (+0.20%) ▲|TMUS188.89+1.59 (+0.85%) ▲|TSLA382.04+25.03 (+7.01%) ▲|TXN253.66-1.14 (-0.45%) ▼|UBER75.81-0.64 (-0.84%) ▼|UNH403.99+4.33 (+1.08%) ▲|UNP291.37+1.64 (+0.57%) ▲|UPS103.30+0.29 (+0.28%) ▲|USB63.55+0.78 (+1.23%) ▲|V377.27-1.14 (-0.30%) ▼|VZ50.74+0.52 (+1.03%) ▲|WFC89.24-0.03 (-0.03%) ▼|WMT109.09+3.00 (+2.83%) ▲|XOM163.58-0.58 (-0.35%) ▼|AAPL328.22+3.26 (+1.00%) ▲|ABBV260.89-0.83 (-0.32%) ▼|ABT108.63-1.85 (-1.67%) ▼|ACN194.49+6.81 (+3.63%) ▲|ADBE284.31+4.52 (+1.61%) ▲|AMAT435.58-2.88 (-0.66%) ▼|AMD457.58+0.52 (+0.11%) ▲|AMGN444.03+1.19 (+0.27%) ▲|AMT177.67+4.75 (+2.75%) ▲|AMZN258.45+3.47 (+1.36%) ▲|AVGO354.44-12.80 (-3.49%) ▼|AXP330.27+0.29 (+0.09%) ▲|BA208.90+0.03 (+0.01%) ▲|BAC63.04+0.44 (+0.69%) ▲|BKNG196.53-3.07 (-1.54%) ▼|BLK1,115.05+7.97 (+0.72%) ▲|BMY67.86+0.20 (+0.29%) ▲|BNY163.70+1.66 (+1.02%) ▲|BRK-B507.73+2.49 (+0.49%) ▲|C137.87+3.53 (+2.62%) ▲|CAT796.71+4.43 (+0.56%) ▲|CL90.29+0.19 (+0.21%) ▲|CMCSA26.62-0.19 (-0.70%) ▼|COF219.85+3.25 (+1.50%) ▲|COP136.18-1.02 (-0.74%) ▼|COST928.93+0.45 (+0.05%) ▲|CRM264.64+7.71 (+3.00%) ▲|CSCO109.03-0.43 (-0.39%) ▼|CVS97.77+0.54 (+0.56%) ▲|CVX212.65+0.87 (+0.41%) ▲|DE693.95-4.42 (-0.63%) ▼|DHR208.54-1.37 (-0.65%) ▼|DIS107.62-0.36 (-0.33%) ▼|DUK121.66+1.10 (+0.91%) ▲|EMR149.81+0.83 (+0.55%) ▲|FDX320.65+4.11 (+1.30%) ▲|GD364.06-0.01 (0.00%) ▼|GE332.16+2.66 (+0.81%) ▲|GEV942.92+20.98 (+2.28%) ▲|GILD149.98+0.37 (+0.25%) ▲|GM86.82+1.95 (+2.30%) ▲|GOOG338.90+5.12 (+1.53%) ▲|GOOGL342.31+5.19 (+1.54%) ▲|GS1,034.79+30.37 (+3.02%) ▲|HD318.96+2.78 (+0.88%) ▲|HON207.92+1.85 (+0.90%) ▲|IBM233.68+1.98 (+0.85%) ▲|INTC91.24+1.19 (+1.32%) ▲|INTU347.75+4.81 (+1.40%) ▲|ISRG370.25-1.64 (-0.44%) ▼|JNJ278.23+3.02 (+1.10%) ▲|JPM361.28+5.06 (+1.42%) ▲|KO88.96+0.72 (+0.82%) ▲|LIN483.22-2.63 (-0.54%) ▼|LLY1,159.84-0.25 (-0.02%) ▼|LMT531.82+0.27 (+0.05%) ▲|LOW202.50+2.66 (+1.33%) ▲|LRCX287.79-0.53 (-0.18%) ▼|MA584.13-4.01 (-0.68%) ▼|MCD259.17-1.78 (-0.68%) ▼|MDLZ61.29-1.16 (-1.86%) ▼|MDT92.77+0.59 (+0.63%) ▲|META612.97+20.12 (+3.39%) ▲|MMM167.92-0.83 (-0.49%) ▼|MO69.87+0.31 (+0.44%) ▲|MRK151.70+0.06 (+0.04%) ▲|MS216.37+4.55 (+2.15%) ▲|MSFT510.21+13.39 (+2.70%) ▲|MU940.98-15.11 (-1.58%) ▼|NEE83.99+0.89 (+1.07%) ▲|NFLX82.32-0.41 (-0.50%) ▼|NKE38.58+0.34 (+0.88%) ▲|NOW143.96+7.24 (+5.30%) ▲|NVDA227.10+2.69 (+1.20%) ▲|ORCL154.63+8.88 (+6.09%) ▲|PEP139.76-0.77 (-0.54%) ▼|PFE28.81-0.21 (-0.72%) ▼|PG147.69+0.05 (+0.03%) ▲|PLTR182.95+13.49 (+7.96%) ▲|PM187.63-0.32 (-0.17%) ▼|QCOM169.26+0.22 (+0.13%) ▲|RTX201.61+0.83 (+0.41%) ▲|SBUX106.14-0.58 (-0.54%) ▼|SCHW110.13+1.89 (+1.75%) ▲|SO89.14+0.83 (+0.94%) ▲|SPG211.31+1.11 (+0.53%) ▲|T26.18+0.23 (+0.87%) ▲|TMO609.78+1.24 (+0.20%) ▲|TMUS188.89+1.59 (+0.85%) ▲|TSLA382.04+25.03 (+7.01%) ▲|TXN253.66-1.14 (-0.45%) ▼|UBER75.81-0.64 (-0.84%) ▼|UNH403.99+4.33 (+1.08%) ▲|UNP291.37+1.64 (+0.57%) ▲|UPS103.30+0.29 (+0.28%) ▲|USB63.55+0.78 (+1.23%) ▲|V377.27-1.14 (-0.30%) ▼|VZ50.74+0.52 (+1.03%) ▲|WFC89.24-0.03 (-0.03%) ▼|WMT109.09+3.00 (+2.83%) ▲|XOM163.58-0.58 (-0.35%) ▼|
29.8 C
New York
Thursday, September 3, 2026

Tag: biopharmaceutical company

newssourceFORcompanyinformationcontent1releasesmarket

Azitra, Inc. to Present at 2026 BIO International Convention

BRANFORD, Conn., June 16, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision...

Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development

Claret Capital Partners is providing growth funding of €43m as part of Inventiva’s €130m debt financing, to support its lead asset through Phase 3.

Innovative Molecules Expands Virology Pipeline with Novel EBV Antiviral Program

MUNICH, June 16, 2026 /PRNewswire/ -- Innovative Molecules GmbH ("IM"), a clinical-stage biopharmaceutical company focused on herpesvirus-mediated diseases, today announced the advancement of its virology...

Minghui Pharmaceutical Presents Compelling Phase I/II Results for MHB018A, a Novel Subcutaneous Anti-IGF-1R Antibody for Thyroid Eye Disease, in an Oral Presentation at ENDO...

MHB018A demonstrated outstanding clinical activity in both active and chronic thyroid eye diseaseAt 450 mg Q4W, MHB018A achieved a remarkable 81% proptosis response at...

Lonza Issues Exclusive, Target-Specific License to Antharis Therapeutics to Advance Next-Generation Dual Payload ADCs for Gastrointestinal Cancers

Target-specific licensing agreement enabling Antharis to advance proprietary dual-payload antibody-drug conjugate (ADC) programs using Lonza's site-specific ADC technologiesReinforces Antharis' and Lonza's position at the forefront...

Enterome presents Phase 1/2 iNHL interim data at EHA demonstrating durable OncoMimics™-induced CD8 T cell responses and clinical activity

Enterome presented new interim data from the ongoing Phase 1/2 SIDNEY study of OncoMimics™ EO2463 in patients with indolent non-Hodgkin lymphoma.

Lundbeck presents new Phase II asedebart data in Cushing’s disease at ENDO 2026

Asedebart is an investigational monoclonal antibody designed to neutralize excess adrenocorticotropic hormone (ACTH) and reduce downstream cortisol production in Cushing's disease (CD)Urinary free cortisol...

Lundbeck presents new Phase II asedebart data in Cushing’s disease at ENDO 2026

Asedebart is an investigational monoclonal antibody designed to neutralize excess adrenocorticotropic hormone (ACTH) and reduce downstream cortisol production in Cushing's disease (CD)Urinary free cortisol...

CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026

SHANGHAI, June 14, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces poster...

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery...

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that seventeen clinical updates from its core assets were presented at the 31st Congress of the European Hematology Association (EHA2026), including eight poster presentations. The presentations featured data from ongoing clinical studies of olverembatinib (HQP1351), the first third-generation BCR-ABL1 inhibitor approved in China, and lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor. The EHA2026 Congress convened in Stockholm, Sweden, from June 11 to 14, 2026.

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBiopharmaceutical company

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers